이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

건선 관절염 참가자의 구셀키맙 치료 지속성에 관한 연구 (PEGASUS)

2026년 11월 2일 업데이트: Janssen-Cilag Ltd.

건선관절염 환자에서 Guselkumab 치료 지속성에 대한 실제 임상환경에서의 전향적 연구

This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).

연구 개요

상태

모병

연구 유형

관찰

등록 (추정된)

200

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

      • Lille, 프랑스, 59037
        • 모병
        • Hopital Roger Salengro - CHU Lille

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The study population will include participants affected with psoriatic arthritis (PsA) according to classification for psoriatic arthritis (CASPAR) criteria.

설명

Inclusion criteria:

  • Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)
  • Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study
  • Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication
  • The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations
  • Must have received the information note, given his/her oral agreement and has not objected to the collection of his/her data in accordance with French requirements

Exclusion Criteria:

  • Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.
  • Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase [JAK] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA/PsO at the same time
  • Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)
  • Unwilling or unable to participate in long-term data collection
  • Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)
  • Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study
  • Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
Group 1: Psoriatic Arthritis Participants Treated With Guselkumab

Participants with confirmed diagnosis of psoriatic arthritis treated with guselkumab as per routine clinical practice will be enrolled. No drug will be provided as part of this study. Only data available within routine clinical practice will be collected in this study.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants Still Receiving Treatment at 1 Year
기간: At 1 year

Discontinuation or maintenance of guselkumab treatment will be recorded by the physician at each visit. Proportion of participants still receiving treatment will be reported in the outcome measure.

At 1 year
Percentage of Participants Still Receiving Treatment at Persistence Time
기간: Up to 8 weeks

Persistence time of the initial treatment: defined as the time from the date of the first administration of guselkumab to the date that the last dose of guselkumab treatment was administered plus 1 dosing interval (8 weeks), or until start of subsequent treatment.

Up to 8 weeks
Number of Participants Starting New Treatment
기간: At 1 year

Participants starting new treatment along with reason of discontinuation will be reported.

At 1 year

2차 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Still Receiving Treatment at 2 years
기간: At 2 years

Percentage of participants still receiving treatment at 2 years will be reported.

At 2 years
Percentage of Participants Discontinuing The Treatment
기간: At 2 years

Participants discontinuing the treatment along with the reasons will be reported.

At 2 years
Change From Baseline in Disease Activity Index in Psoriatic Arthritis (DAPSA)/ Clinical Disease Activity Index in Psoriatic Arthritis (cDAPSA)
기간: Baseline, Months 3,6,12,18, and 24

The DAPSA was developed to characterize psoriatic arthritis (PsA) disease activity. It considers the number of painful and swollen joints, the patient's assessment of their disease and the C-reactive protein (CRP) measurement for acute inflammation. Where CRP measurements are not available, the clinical DAPSA (cDAPSA) maybe be used, which omits CRP. An overall score is calculated, where higher scores correspond to higher disease activity. Cut-off values for DAPSA low and high disease activity are: ≤14 and >28 points, respectively, and for remission is ≤4 points. The cut-off values for cDAPSA are: ≤4 points for remission, >4 to ≤13 points for low disease activity, > 13 to ≤27 points for moderate disease activity, and >27 points for high disease activity.

Baseline, Months 3,6,12,18, and 24
Change From Baseline in Leeds Enthesitis Index (LEI) Score
기간: Baseline, Months 3,6,12,18, and 24

The Leeds enthesitis index (LEI) measures the activity of enthesitis in PsA. The index measures the severity and activity of enthesitis, inflammation at the attachment of the ligaments and tendons to bone. The clinical assessor must elicit tenderness at 6 enthesitis sites: both lateral epicondyles of the humerus, both medial condyles of the femur, and the Achilles tendon insertions. Each site affected is summed to give a score out of 6, where 6 indicates all sites affected.

Baseline, Months 3,6,12,18, and 24
Change From Baseline in Back and Neck Pain Numerical Rating Scale (NRS) Score
기간: Baseline, Months 3,6,12,18, and 24

NRS for back and neck pain will be administered. This is a simple numbered 0-10 scale on which the patient indicates the intensity of their pain (0 represents no pain and 10 indicates the worst possible pain).

Baseline, Months 3,6,12,18, and 24
Hazard Ratios Between Baseline Clinical Factors and Guselkumab Persistence and Effectiveness at Months 12 and 24
기간: At Month 12 and 24

Hazard ratios for association between baseline clinical factors and persistence/effectiveness from Cox proportional hazards models will be reported.

At Month 12 and 24
Sociodemographic Characteristics: Age
기간: At Baseline

Participant's age will be reported.

At Baseline
Sociodemographic Characteristics: Sex
기간: At Baseline

Participant's sex (male, female) will be reported

At Baseline
Sociodemographic Characteristics: Weight
기간: At Baseline

Participant's weight will be reported

At Baseline
Sociodemographic Characteristics: Height
기간: At Baseline

Participant's height will be reported.

At Baseline
Sociodemographic Characteristics: Body Mass Index (BMI)
기간: At Baseline

Participant's BMI will be reported.

At Baseline
Number of Participants Reporting Smoking, Cannabis and Alcohol Use
기간: At Baseline

Participant's smoking, use of Cannabis and Alcohol habit will be reported.

At Baseline
Number of Participants With Family History of Psoriasis and/or Psoriatic Arthritis and/or Spondyloarthritis
기간: At Baseline

Family history of psoriasis and/or psoriatic arthritis and/or spondyloarthritis wil be reported.

At Baseline
Date of Diagnosis of Psoriatic Arthritis
기간: At Baseline

Date of diagnosis of psoriatic arthritis will be reported.

At Baseline
Date of Previous Treatments of Psoriatic Arthritis
기간: At Baseline

Date of previous treatments of psoriatic arthritis will be reported.

At Baseline
Duration of Previous Treatments of Psoriatic Arthritis
기간: At Baseline

Duration of previous treatments of psoriatic arthritis will be reported.

At Baseline
Medical History and Current Situation
기간: At Baseline

Participants medical history and current medical situation will be reported.

At Baseline
Number of Participants Receiving Co-occurring Treatments Linked to Psoriatic Arthritis
기간: Baseline up to 2 Years

Participants receiving co-occurring treatments linked to psoriatic arthritis at baseline and during follow-up will be reported.

Baseline up to 2 Years
Failure to Achieve or Maintain Response
기간: Up to 2 Years

Failure to achieve or maintain response to at least 2 biologic/targeted synthetic DMARDs with at least 2 different mechanisms of action (Y/N) (For treatment refractory criteria).

Up to 2 Years
Number of Participants Reporting Problems Related to the Management of Signs and Symptoms
기간: At baseline

The management of signs and/or symptoms that is perceived as problematic by the rheumatologist and/or the participants will be reported.

At baseline
Evidence of Persistent Disease
기간: Up to 2 Years

Evidence of persistent disease as defined by at least 2 of the following: a) failure to achieve or maintain low disease activity, b) the presence of active extra-musculoskeletal manifestations of PsA, c) objective evidence of inflammatory activity, namely clinical signs, elevated acute phase reactants and/or imaging findings suggestive of inflammation.

Up to 2 Years
Number of Participants with Co-Morbidities
기간: At baseline

Number of participants with co-morbidities will be reported.

At baseline
Number of Participants with Abnormal Psychosocial Factors
기간: At Baseline

Number of participants with abnormal psychosocial factors will be reported.

At Baseline
Healthcare Professional (HCP): Age Group
기간: At Baseline

Age group of HCP will be reported.

At Baseline
HCP: Sex
기간: At Baseline

Sex of HCP will be reported.

At Baseline
HCP: Experience
기간: At Baseline

Experience of HCP will be reported.

At Baseline
HCP: Type of Practice
기간: At Baseline

Type of practice of HCP will be reported.

At Baseline
Number of Participants With Adverse Events, Serious Adverse Events, Infections and Injection Site Reactions
기간: Up to 2 Years

AEs with onset or worsening on or after date of first dose of study treatment. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1 equal (=) Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to AE. SAE is any untoward medical occurrence that results in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Up to 2 Years
Tolerance Related Guselkumab Treatment
기간: Up to 2 Years

Tolerance Related guselkumab treatment will be reported.

Up to 2 Years
Dose at Initiation of Guselkumab
기간: At Months 0, 3, 6, 12, 18 and 24

Dose at initiation of guselkumab will be reported.

At Months 0, 3, 6, 12, 18 and 24
Treatment Interval at Initiation of Guselkumab
기간: At Months 0, 3, 6, 12, 18 and 24

Treatment interval at initiation of guselkumab will be reported.

At Months 0, 3, 6, 12, 18 and 24
Type of Injection
기간: At Months 0, 3, 6, 12, 18 and 24

Type of injection will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants Reporting Change of Injection Frequency
기간: At Months 0, 3, 6, 12, 18 and 24

Participants reporting change of injection frequency (Q4 to Q8 or Q8 to Q4) and its reason will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participant With Co-occurring Treatments Linked to PSA
기간: At Months 0, 3, 6, 12, 18 and 24

Participants with co-occurring treatments linked to PSA will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants With Reason for Choosing Guselkumab From the Therapeutic Arsenal
기간: At Months 0, 3, 6, 12, 18 and 24

Participants with reason for choosing guselkumab from the therapeutic arsenal will be reported.

At Months 0, 3, 6, 12, 18 and 24
Number of Participants Switching to New Treatment in Case of Discontinuation of Guselkumab Treatment
기간: At Months 0, 3, 6, 12, 18 and 24

Participants switching to new treatment in case of discontinuation of guselkumab treatment will be reported.

At Months 0, 3, 6, 12, 18 and 24
Change From Baseline in 12-item Psoriatic Arthritis Impact of Disease Questionnaire (PsAID-12) Questionnaire Score
기간: Baseline, Months 0, 3, 6, 12, 18 and 24

The PsAID-12 questionnaire was designed to assess the impact of disease, with questions on pain, physical function, fatigue, coping and depression. It is a validated, self-administered questionnaire developed for use in clinical practice that assesses the impact of PsA on patients' lives. It consists of 12 questions, each answered using a numerical rating scale. Questions related to pain, skin problems, work and/or leisure activities, discomfort, embarrassment and/or shame, social participation, and anger, fear, and uncertainty, and depression are scored from 0 (none) to 10 (extreme), functional capacity and sleep disturbance are scored from 0 (no difficulty) to 10 (extreme difficulty) and coping is scored from 0 (very well) to 10 (very poorly).

Baseline, Months 0, 3, 6, 12, 18 and 24
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Each Visit After Baseline
기간: Baseline, Months 0, 3, 6, 12, 18 and 24

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was developed to measure disease activity in patients with ankylosing spondylitis. It consists of 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain/swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration and morning stiffness severity. Each symptom is assessed on a scale of 0-10 where 0 indicates no pain or discomfort and 10 indicates maximum pain or discomfort. To give each symptom equal weighting, the mean (average) of the 2 scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease.

Baseline, Months 0, 3, 6, 12, 18 and 24
Satisfaction of Treatment for the Participants
기간: At Months 3, 6, 12, 18 and 24

The satisfaction of treatment for the participant will be assessed using a 5-point Likert scale, ("Very dissatisfied Dissatisfied Neither satisfied nor dissatisfied Satisfied Very satisfied"). The scale includes two patient reported questions: "1) How satisfied or dissatisfied are you with the overall convenience of this medication" and "2) How satisfied or dissatisfied are you with the ability of this medication ability to treat your condition?" Scores range from Very dissatisfied to Very satisfied and will be used to evaluate satisfaction with guselkumab treatment.

At Months 3, 6, 12, 18 and 24
Satisfaction of Treatment Care Management and Patient Relationship for the Rheumatologist
기간: At Months 3, 6, 12, 18 and 24

Satisfaction of treatment care management and patient relationship for the rheumatologist will be assessed using a 5-point Likert scale specified as : "Very dissatisfied, Dissatisfied, Neither satisfied nor dissatisfied, Satisfied and Very satisfied." The physician-reported questions are: "1) How satisfied or dissatisfied are you with this drug overall for this patient?" and "2) How satisfied or dissatisfied are you with the ease of managing your patient with guselkumab?"

At Months 3, 6, 12, 18 and 24

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Janssen-Cilag France Clinical Trial, Janssen-Cilag France

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 4월 17일

기본 완료 (추정된)

2029년 12월 10일

연구 완료 (추정된)

2029년 12월 10일

연구 등록 날짜

최초 제출

2026년 4월 8일

QC 기준을 충족하는 최초 제출

2026년 4월 8일

처음 게시됨 (실제)

2026년 4월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CNTO1959PSA4021
  • CNTO1959PSA4021 (기타 식별자: Janssen Research & Development, LLC)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다